Glenmark Pharma launches generic version of Novartis heart failure drug
The cardiac drug market in India, worth 200 billion rupees, is set to change as generic versions of Novartis’ heart failure medication Vymada are introduced. On Monday, Glenmark Pharmaceuticals, based